Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DK 2-10

Next Previous
X
Search
Drug Profile

DK 2-10

Alternative Names: DK-210; Next-generation targeted cytokine therapy

Latest Information Update: 10 Jul 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Deka Biosciences
  • Class Antineoplastics; Cytokines; Drug conjugates; Immunoconjugates; Immunoglobulin Fv fragments; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Interleukin 10 replacements; Interleukin 2 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Haematological malignancies; Renal cell carcinoma

Most Recent Events

  • 31 May 2024 Efficacy, pharmacokinetic and adverse events data from a phase I trial in Solid tumour presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 25 Sep 2023 Preclinical trials in Haematological malignancies in USA (SC), prior to September 2023 (Deka Biosciences pipeline, September 2023)
  • 23 Feb 2023 Phase-I clinical trials in Solid tumours (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (SC, Liquid) (NCT05704985)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top